Elotuzumab

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 431 publications

A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM).

A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM).

Journal: Expert opinion on biological therapy

Published: March 17, 2026

Risk of adverse events in elotuzumab-treated patients with multiple myeloma: a systematic review and meta-analysis.

Risk of adverse events in elotuzumab-treated patients with multiple myeloma: a systematic review and meta-analysis.

Journal: Annals of medicine

Published: March 12, 2026

Comparison of adverse event profiles of carfilzomib-, elotuzumab-, and ixazomib-based therapies combined with lenalidomide and dexamethasone in patients with multiple myeloma using VigiBase.

Comparison of adverse event profiles of carfilzomib-, elotuzumab-, and ixazomib-based therapies combined with lenalidomide and dexamethasone in patients with multiple myeloma using VigiBase.

Journal: Leukemia research

Published: March 02, 2026

The Anti-SLAMF7 Antibody, Elotuzumab, Induces Antibody-Dependent Cellular Cytotoxicity Against CLL Cell Lines.

The Anti-SLAMF7 Antibody, Elotuzumab, Induces Antibody-Dependent Cellular Cytotoxicity Against CLL Cell Lines.

Journal: Molecules (Basel, Switzerland)

Published: December 22, 2025

Cyclophosphamide-pomalidomide combination alters the tumour cell secretome and enhances the anti-myeloma activity of elotuzumab through NK cell-mediated cytotoxicity.

Cyclophosphamide-pomalidomide combination alters the tumour cell secretome and enhances the anti-myeloma activity of elotuzumab through NK cell-mediated cytotoxicity.

Journal: International immunopharmacology

Published: November 18, 2025

Elotuzumab enhances the anti-tumor activity of Vγ9Vδ2 T cells against primary effusion lymphoma.

Elotuzumab enhances the anti-tumor activity of Vγ9Vδ2 T cells against primary effusion lymphoma.

Journal: European journal of pharmacology

Published: October 18, 2025

Gastrointestinal toxicity in the treatment of hematological tumors. Influence on nutritional status.

Gastrointestinal toxicity in the treatment of hematological tumors. Influence on nutritional status.

Journal: Endocrinologia, diabetes y nutricion

Published: October 01, 2025

SLAMF7: A Potential Target for CAR T-Cell Therapy in Multiple Myeloma.

SLAMF7: A Potential Target for CAR T-Cell Therapy in Multiple Myeloma.

Journal: Cancers

Published: September 23, 2025

Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy: roles of underlying diseases and immunomodulatory therapies in FAERS.

Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy: roles of underlying diseases and immunomodulatory therapies in FAERS.

Journal: Frontiers in immunology

Published: September 17, 2025

Cardiovascular Toxicity of Monoclonal Antibodies Approved for Multiple Myeloma: Evidence Based on FAERS Database.

Cardiovascular Toxicity of Monoclonal Antibodies Approved for Multiple Myeloma: Evidence Based on FAERS Database.

Journal: Therapeutic innovation & regulatory science

Published: August 17, 2025

Cardiac Adverse Events Associated With Elotuzumab: A Disproportionality Analysis Using FDA Adverse Event Reporting System.

Cardiac Adverse Events Associated With Elotuzumab: A Disproportionality Analysis Using FDA Adverse Event Reporting System.

Journal: The Annals of pharmacotherapy

Published: August 04, 2025

Daratumumab (anti-CD38)- and elotuzumab (anti-SLAMF7)-based treatments for refractory POEMS syndrome: a single-center case series.

Daratumumab (anti-CD38)- and elotuzumab (anti-SLAMF7)-based treatments for refractory POEMS syndrome: a single-center case series.

Journal: Hematology (Amsterdam, Netherlands)

Published: June 18, 2025

Showing 1-12 of 431

Last Updated: 06/30/2026